revascularization to include total occlusions refractory to conventional techniques, then the instrument would gain in importance to the interventionalist.
The earliest attempts to use laser angioplasty for totally occluded vessels were carried out jointly by a team of cardiologists and radiologists2 and produced an unacceptable incidence of mechanical perforations due to the bayonnettelike effect of the bare optical fiber. Hussein et a13 solved the problem of mechanical perforation by applying a corpulent metal cap to the distal end of the optical fiber; this novel tip design promoted coaxial, intraluminal passage of the optical fiber and used the laser light to heat the metal cap, thereby burning away atherosclerotic plaque.
While clinical applications of so-called "hot-tip laser angioplasty" served to focus attention on the issue of long total occlusions in lower-extremity vascular disease,4 the apparent niche that had developed for laser angioplasty was rendered nonexclusive by two concurrent developments. First, McNamara and Fischer5 demonstrated that adjuvant thrombolytic therapy frequently converted total occlusions to subtotal occlusions, which were then easily treated by conventional angioplasty. Second, development of the hydrophilic ("glide," "eel," or "slime,") wire dramatically improved the capability of the interventionalist to atraumatically recanalize long total occlusions with just a guide wire. 6 The risk inherent in the atherectomy strategy, however, is illustrated in the superb clinical investigation reported by Karsch et a124 in this issue of Circulation. Despite the fact that 44 of 60 procedures (73%) were acutely successful -including 23 patients treated by laser angioplasty alone (i.e., no supplementary balloon dilation) -short-term angiographic follow-up of 28 patients disclosed evidence of restenosis in 16 (57%). Moreover, although the number of cases was small, excimer laser angioplasty in patients with unstable angina, and perhaps unstable plaque morphololgy, was not without risk. Finally, contrary to the in vitro and in vivo animal data cited above, excimer laser angioplasty was in certain instances complicated by apparent spasm.
The explanation for the latter finding remains enigmatic but has also been observed by those using the two other systems currently approved for investigational use. Previous reports from our laboratory demonstrated that even with a pulsed laser such as the excimer, excessive irradiation resulting from either protracted cumulative exposure or excessive repetition rate could produce thermal injury.14,25 Consistent with this finding is the recent European experience (with the system used by Karsch et a124) that the incidence of spasm may be diminished by reducing the duration of individual exposures. Alternatively, spasm in patients treated by pulsed laser angioplasty may result from focal heating at a site where the character of the lesion or contour of the artery resists facile advancement of the multifiber catheter. Finally, the possibility that spasm may have resulted from the relatively large (9F) guiding catheters or excessive coronary intubation used to power a multifiber catheter with a relatively stiff and inflexible tip cannot be excluded.
Whatever the reason, it is important to put these exceptional results in perspective. First, in pointed contrast to experience with the hot-tip technology, spasm did not complicate most cases of coronary laser angioplasty in this series. Second, while Karsch et a124 did not attempt to do so, it is possible that the excimer laser might have been used to reverse spasm in these cases by exploiting the photorelaxation property of low doses of excimer laser light. 26 That excimer laser angioplasty failed to obviate the problem of restenosis is due at least in part to certain features of the prototypical multifiber catheters presently used with these systems. As Karsch et al acknowledge,24 the flexibility of the catheters used for their procedures was suboptimal. Consequently, most cases (41 of 55, or 74%) involved the left anterior descending coronary artery, the proximal segment of which has been previously recognized to be an independent anatomical risk factor for restenosis.
Perhaps most important, however, is teasing out the contribution of adjunctive balloon angioplasty to restenosis after excimer laser angioplasty. One of the major dilemmas that has confounded the development of fiber-catheter delivery systems is how to reconcile the requirement of diminutive, flexible optical fibers or fiber bundles with the intent to achieve an adequate-size lumen with laser irradiation alone. A key question is the extent to which restenosis is an independent function of residual luminal diameter narrowing. Liu et al27 recently reviewed the incidence of restenosis as a function of residual luminal diameter narrowing in more than 2,000 patients treated by balloon angioplasty for one-vessel disease; among patients with less than 50% luminal diameter narrowing after angioplasty, the incidence of restenosis was the same for those with 35-49% as it was for those with 0-19% residual diameter narrowing.
This finding has been implicitly incorporated into many current clinical trials of excimer laser angioplasty to determine whether the long-term outcome of a patient with an arbitrary noncritical percent of residual luminal diameter narrowing achieved with excimer laser angioplasty alone is superior to no (or least) residual luminal narrowing achieved by combined laser-balloon angioplasty. Karsch et a124 analyzed a small subgroup (23) among their cohort in whom this strategy had been used and still found a restenosis rate of 32% (six of 19) among patients in whom angiographic follow-up was available after laser angioplasty alone.
Until catheters designed for excimer laser angioplasty approach a stage of development similar to that of balloon angioplasty catheters, any assessment of restenosis must be regarded as premature. It is important to understand that for more than two decades, the principal thrust of research in fiberoptics was aimed at satisfying the telecommunications industry; accordingly, this involved transmission of low powers by large-diameter fibers.16 In contrast, percutaneous vascular therapy requires transmission of peak powers in the megawatt or kilowatt range by fiberoptics sufficiently small to traverse the angles and bends of the coronary arteries.
Postprocedural testing of the fiberoptic catheters used by Karsch et warrants close attention as attempts to create a larger lumen at sites of highly calcified obstructions become more ambitious. While definitive data are still pending and conventional wisdom suggests that unscheduled DNA synthesis is an unlikely consequence of ultraviolet laser irradiation,32 the possibility that certain wavelengths may be more likely to facilitate accelerated smooth muscle cell proliferation (i.e., restenosis) remains unresolved. Finally, from the standpoint of delivery devices, it must be remembered that none of the three ongoing clinical trials of excimer laser angioplasty involve a device designed to recanalize totally occluded arteries.
Despite these unresolved issues, ongoing clinical investigation of excimer laser atherectomy has restored credibility to the concept of percutaneous laser revascularization. The most sophisticated biomedical lasers yet engineered have resuscitated a technology that is now closer than ever before to fulfilling the promise that has intrigued both investigators and investors for more than a decade. 
